Analysis and Purification of Antibody Fragments Using Protein A, Protein G, and Protein L

  • Remko GriepEmail author
  • John McDougall
Part of the Springer Protocols Handbooks book series (SPH)


Today, monoclonal antibodies (mAbs) form the largest category of biopharmaceuticals in clinical trials and their number is expanding rapidly (DataMonitor 2007). The antibodies or functional antibody fragments are being produced in artificial production systems like mammalian cells, yeast, bacteria and plant cells but also in transgenic animals like goats, sheep and cows. Regardless of the production method, the quality control demand is the same for all of them. Host cell proteins, cell culture media additives, DNA and endotoxins have to be removed from the mAb preparation to allow the proteins to be safely applied for human therapy. Moreover, antibody aggregates, clipped and low molecular weight species should also be removed.


Antibody Fragment Column Volume Host Cell Protein Periplasmic Fraction Antibody Phage Library 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Åkerström B, Björk L (1989) Protein L: an immunoglobulin light chain binding bacterial protein. J Biol Chem 264:19740–19746PubMedGoogle Scholar
  2. Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E (2008) Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Malar J 7:129–139PubMedCrossRefGoogle Scholar
  3. Björk L, Kronvall G (1984) Purification and some properties of Streptococcal protein G a novel IgG-binding reagent. J Immunol 133:969–974Google Scholar
  4. Boi C, Dimartino S, Sarti GC (2008) Performance of a new protein A affinity membrane for the primary recovery of antibodies. Biotech Prog 24:640–647CrossRefGoogle Scholar
  5. Bonifacino JS, Dell’Angelica EC (1998) Immunoprecipitation. Curr Protoc Cell Biol Chapter 7:7.2.1–7.2.21Google Scholar
  6. Carter-Franklin JN, Victa C, McDonald P, Fahrner R (2007) Fragments of protein A eluted during protein A chromatography. J Chromatog A 1163:105–111CrossRefGoogle Scholar
  7. Cossins AJ, Harrison S, Popplewell AG, Gore MG (2007) Recombinant production of a VL single domain antibody in Escherichia coli and analysis of its interaction with peptostreptococcal protein L. Protein Expr Purif 51:253–259PubMedCrossRefGoogle Scholar
  8. Das D, Allen TM, Suresh MR (2005) Comparative evaluation of two purification methods of anti-CD19-c-myc-His6-Cys scFv. Protein Expr Purif 39:199–208PubMedCrossRefGoogle Scholar
  9. DataMonitor (2007) Monoclonal Antibodies Report Market Model – Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2012, evaluating the strategies companies are using to capitalize on this lucrative market. Reference Code: IMHC0090, June 2007Google Scholar
  10. DataMonitor (2007) Monoclonal Antibodies Report Part 1. Reference Code: DMHC2291, June 2007Google Scholar
  11. De Château M, Nilson BH, Erntell M, Myhre E, Magnusson CG, Akerström B, Björck L (1993) On the interaction between protein L and immunoglobulins of various mammalian species. Scand J Immunol 37:339–405CrossRefGoogle Scholar
  12. Devaux C, Moreau E, Goyffon M, Rochat H, Billiald P (2001) Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur J Biochem 268:694–702PubMedCrossRefGoogle Scholar
  13. Eliasson M, Olsson A, Palmcrantz E, Wiberg K, Inganäs M, Guss B, Lindberg M, Uhlén M (1988) Chimeric IgG-binding receptors engineered from staphylococcal protein A and streptococcal protein G. J Biol Chem 263:4323PubMedGoogle Scholar
  14. Enever C, Tomlinson IA, Lund J, Levens M, Holliger P (2005) Engineering high affinity superantigens by phage display. J Mol Biol 347:107–120PubMedCrossRefGoogle Scholar
  15. Fahrner RL, Whitney DH, Vanderlaan M, Blank GS (1999) Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol Appl Biochem 30:121–128PubMedGoogle Scholar
  16. Forsgren A, Sjöquist J (1966) Protein A from staphylococcus Aureus I Pseudoimmune reaction with human gamma-globulin. J Immunol 97:822–827PubMedGoogle Scholar
  17. Fuglistaller P (1989) Comparison of immunoglobulin binding capacities and ligand leakage using eight different protein A affinity chromatography matrices. J Immunol Methods 124:171–177PubMedCrossRefGoogle Scholar
  18. Ghose S, Allen M, Hubbard B, Brooks C, Cramer SM (2005) Antibody variable region interactions with protein A: Implications for the development of generic purification process. Biotechnol Bioeng 92:665–673PubMedCrossRefGoogle Scholar
  19. Ghose S, Hubbard B, Cramer SM (2007) Binding capacity differences for antibodies and Fc-Fusion proteins on protein A chromatographic materials. Biotechnol Bioeng 96:768–779PubMedCrossRefGoogle Scholar
  20. Godfrey MA, Kwasowsky P, Clift R, Marks V (1993) Assessment of the suitability of commercially available SpA affinity solid phases for the purification of murine monoclonal antibodies at process scale. J Immunol Methods 160:97–105PubMedCrossRefGoogle Scholar
  21. Gülich S, Linhult M, Stål S, Hober S (2002) Engineering streptococcal protein G for increased alkaline stability. Prot Eng 15:835–842CrossRefGoogle Scholar
  22. Hahn R, Schlegel R, Jungbauer A (2003) Comparison of protein A affinity sorbents. J Chromatog B 790:35–51CrossRefGoogle Scholar
  23. Hahn R, Shimahara K, Steindl F, Jungbauer A (2006) Comparison of protein A affinity sorbents III Life time study. J Chromatog A 1102:224–231CrossRefGoogle Scholar
  24. Harrison SL, Housden NG, BottomLey SP, Cossins AJ, Gore MG (2008) Generation of a minimal hybrid Ig-receptor formed between single domains from proteins L and G. Protein Expr purif 58:12–22PubMedCrossRefGoogle Scholar
  25. Hober S, Nord K, Linhult M (2007) Protein A chromatoghraphy for antibody purification. J Chromatog B 848:40–47CrossRefGoogle Scholar
  26. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Prot Eng Des Sel 21:283–288CrossRefGoogle Scholar
  27. Housden NG, Harrison S, Roberts SE, Beckingham JA, Graille M, Stura E, Gore MG (2003) Immunoglobulin-binding domains: Protein L from peptostreptococcus magnus. Biochem Soc Trans 31:716–718PubMedCrossRefGoogle Scholar
  28. Housden NG, Harrison S, Housden HR, Thomas KA, Beckingham JA, Roberts SE, Bottomley SP, Graille M, Stura E, Gore MG (2004) Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human κ light chains. J Biol Chem 279:9370–9378PubMedCrossRefGoogle Scholar
  29. Kastern K, Sjöbring U, Björk L (1992) Structure of peptostreptococcal protein L and identification of a repeated immunoglobulin light chain-binding domain. J Bio Chem 267:12820–12825Google Scholar
  30. Katoh S, Imada M, Takeda N, Katsuda T, Miyahara H, Inoue M, Nakamura S (2007) Optimization of silica-based media for antibody purification by protein A affinity chromatography. J Chromatog A 1161:36–40CrossRefGoogle Scholar
  31. Kihlberg B, Sjöholm AG, Björk L, sjöbring U (1996) Characterization of the binding properties of protein LG, an immunoglobulin binding hybrid protein. Eur J Biochem 240:556–563PubMedCrossRefGoogle Scholar
  32. Kim JY, Mulchandani A, Chen W (2005) Temperature-triggered purification of antibodies. Biotechnol Bioeng 90:373–379PubMedCrossRefGoogle Scholar
  33. LeVan MD, Carta G, Yon CM (1997) Adsorption and ion exchange In: Green DW (ed), Perry’s Chemical engineers Handbook, 7th edn. McGraw-Hill, New York,  Chapter 16 Google Scholar
  34. Linhult M, Gülich S, Gräslund T, Simon A, Karlsson M, Sjöberg A, Nord K, Hober (2004) Improving the tolerance of a protein A analogue to repeated alkaline phosphatase exposures using a bypass mutagenesis approach. Proteins: structure, function, and bioinformatics 55:407–416CrossRefGoogle Scholar
  35. Løset GÅ, Løbersli I, Kavlie K, Stacy JE, Borgen T, Kausmally L, Hvattum E, Simonsen B, Befring Hovda M, Brekke OH (2005) Construction, evaluation and refinement of a large human antibody phage library based on the IgD and IgM variable gene repertoire. J Immunol Methods 299:47–62PubMedCrossRefGoogle Scholar
  36. Nilson BHK, Solomon A, Björk L, Åkerström B (1992) Protein L from peptostreptococcus magnus binds to the κ light chain variable domain. J Biol Chem 267:2234–2239PubMedGoogle Scholar
  37. Shukla AA, Gupta P, Han X (2007) Protein aggregation kinetics during protein A chromatography, a case study for an Fc fusion protein. J Chromatog A 1171:22–28CrossRefGoogle Scholar
  38. Sletta H, Nedal A, Aune TE, Hellebust H, Hakvåg S, Aune R, Ellingsen TE, Valla S, Brautaset T (2004) Broad-host-range plasmid pJB658 can be used for industrial-level production of a secreted host-toxic single-chain antibody fragment in Escherichia coli. Appl Environ Microbiol 70:7033–9039PubMedCrossRefGoogle Scholar
  39. Solomon A (1976) Bence-Jones proteins and light chains of immunoglobulins. N Engl J Med 294:17–23PubMedCrossRefGoogle Scholar
  40. Starovasnik MA, O’Connell MP, Fairbrother WJ, Kelley RF (1999) Antibody variable region binding by staphylococcal protein A: Thermodynamic analysis and location of the Fv binding site on E-domain. Prot Sci 8:1423–1431CrossRefGoogle Scholar
  41. Svensson H, Hoogenboom HR, Sjöbring U (1998) Protein LA, a novel hybrid protein with unique single-chain Fv antibody and Fab binding properties. Eur J Biochem 258:890–896PubMedCrossRefGoogle Scholar
  42. Swinnen K, Krul A, Van Goidsenhoven I, Van Tichelt N, Roosen A, Van Houdt K (2007) Performance comparison of protein A affinity resins for the purification of monoclonal antibodies. J Chromatog B 848:97–107CrossRefGoogle Scholar
  43. Tugcu N, Roush DJ, Göklen KE (2007) Maximizing productivity of chromatography steps for purification of monoclonal antibodies. Biotechnol Bioeng 99:599–613CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Affitech ASOsloNorway

Personalised recommendations